Poetting Sierk
Known title: Chief Operating OfficerCIK: 0001955589
Associated companies
Transaction History
| BNTX | ▼ Sell | Open Market | 50,000 | $5.5M | 4/22/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 50,000 | $5.5M | 4/22/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BioNTech shares slip after cancer trial misses PFS endpoint
BioNTech's shares fell about 7% after a late‑stage mRNA cancer vaccine trial did not meet its primary progression‑free survival goal. The miss has prompted analysts to reassess the company's oncology pipeline and contributed to a broader pullback in the stock. Canaccord Genuity kept its rating but lowered its price target to $132, reflecting the recent results. The stock is trading near a support level around $90.86 and its RSI is in the lower‑mid range.
BioNTech shares slip after cancer trial misses PFS endpoint. BioNTech's shares fell about 7% after a late‑stage mRNA cancer vaccine trial did not meet its primary progression‑free survival goal. The miss has prompted analysts to reassess the company's oncology pipeline and contributed to a broader pullback in the stock. Canaccord Genuity kept its rating but lowered its price target to $132, reflecting the recent results. The stock is trading near a support level around $90.86 and its RSI is in the lower‑mid range.